08.05.2013 - Belgian single chain camelidae antibody producer Ablynx has started development of an anti-IgE nanobody, code-named ALV-0962.
The Ghent-based company announced the compound will enter clinical development after Q2/2014. Ablynx believes its treatment of severe allergic asthma can outcompete Roche’s /Novartis’ marketed allergic asthma antibody Xolair (omalizumab) due to its "unique" dual mode of action. The company suggested the preclinical compound could displace receptor-bound IgE as well as binding free IgE molecules.
Due to its mode of action, Ablynx believes that ALX-0962 could address a wider patient population, including those currently not eligible to be treated with omalizumab (Xolair®). Currently, many allergic asthma treatments are in clinical development including Phase II compounds from Swedish Resistentia Pharmaceuticals AB, Takeda, Actelion or Cytos Biotechnology (CYT003-QbG10).
IgE is a key mediator in initiating an allergic reaction upon allergen exposure. IgE is a clinically and commercially validated mechanism to treat allergic asthma. Omalizumab currently is the only anti-IgE biologic approved for the treatment of patients with moderate to severe persistent allergic asthma, inadequately controlled with inhaled corticosteroids. Xolair® generated sales of $1.26bn in 2012.
26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.
24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.
23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.
17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.
13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.
13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.
10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.
10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.